+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Use of probiotics in prevention and treatment of patients with Clostridium difficile infection



Use of probiotics in prevention and treatment of patients with Clostridium difficile infection



Best Practice and Research. Clinical Gastroenterology 30(1): 111-118



Clostridium difficile is an anaerobic, gram positive, sporulating, toxin-producing bacillus which causes a spectrum of clinical disease ranging from an asymptomatic carrier state to toxic megacolon and fulminant disease. Infection with C. difficile is an expensive and pervasive health care burden. The current theory regarding the development of C. difficile infection (CDI) suggests that disruption of the structure and/or function of an individual's normal intestinal microbiota enables colonization by C. difficile, and in the absence of an effective immune response, the bacteria causes illness. In this article we discuss the role of the colonic microbiota in the development of CDI and the potential role of probiotics in preventing and treating CDI. We review the evidence from in vitro laboratory and pre-clinical studies, as well as evidence from clinical studies and discuss the current recommendations for the use of probiotics for CDI in clinical practice.

(PDF emailed within 0-6 h: $19.90)

Accession: 059216038

Download citation: RISBibTeXText

PMID: 27048902

DOI: 10.1016/j.bpg.2016.01.002


Related references

Probiotics for Prevention and Treatment of Clostridium difficile Infection. Advances in Experimental Medicine and Biology 1050: 161-176, 2018

Probiotics for Prevention of Clostridium difficile Infection in Hospitalized Patients: Is the Jury Still Out?. Gastroenterology 152(8): 1817-1819, 2017

Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age and Ageing 41(6): 706-711, 2013

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients systematic review and meta-analysis. 2013

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Medicine 7(2): E56-E67, 2014

Probiotics and prevention of Clostridium difficile infection. Anaerobe 45: 114-119, 2016

Probiotics for prevention of Clostridium difficile infection. Current Opinion in Gastroenterology 34(1): 3-10, 2017

Prevention of Clostridium difficile Infection With Probiotics. Clinical Infectious Diseases 60 Suppl 2: S122-S128, 2016

Is primary prevention of Clostridium difficile infection possible with specific probiotics?. International Journal of Infectious Diseases 16(11): E786-E792, 2013

Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therapeutic Advances in Gastroenterology 4(3): 185-197, 2011

Risks of Saccharomyces boulardii-Containing Probiotics for the Prevention of Clostridium difficile Infection in the Elderly. Gastroenterology 153(5): 1450-1451, 2017

Current status of probiotics usage for the prevention of a first episode of Clostridium difficile infection. Revue Medicale Suisse 14(623): 1834-1837, 2018

Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection. PharmacoTherapy 35(11): 1016-1025, 2017

The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterology Clinics of North America 41(4): 763-779, 2013

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology 101(4): 812-822, 2006